Overcoming acquired resistance following osimertinib administration in EGFR-mutant lung adenocarcinoma

Transl Lung Cancer Res. 2024 May 31;13(5):1177-1182. doi: 10.21037/tlcr-24-193. Epub 2024 May 27.

Authors

Kyoichi Kaira¹, Hisao Imai¹, Hiroshi Kagamu¹

Affiliation

¹ Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka City, Japan.

No abstract available

Keywords: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs); dacomitinib; osimertinib; overcome; resistance.

Publication types

Editorial
Comment